NESP

NESP

darbepoetin alfa

Manufacturer:

Kyowa Kirin

Distributor:

DCH Auriga - Healthcare
/
Four Star
Concise Prescribing Info
Contents
Darbepoetin α
Dosage/Direction for Use
IV Hemodialysis patient Initial dose: 20 mcg single inj once wkly. When switching from erythropoietin prep: Initially 15-60 mcg single inj once wkly. Maintenance dose: 15-60 mcg single inj once wkly. If alleviation of anemia is maintained by once wkly inj, dose can be changed to 2-fold of the initial dose, administered once every 2 wk. Max: 180 mcg single inj. SC/IV Peritoneal dialysis patient & patient w/ CKD not on dialysis Initial dose: 30 mcg single inj once every 2 wk. When switching from erythropoietin prep: Initially 30-120 mcg single inj once every 2 wk. Maintenance dose: 30-120 mcg single inj once every 2 wk. If alleviation of anemia is maintained by once every 2 wk inj, dose can be changed to 2-fold of the initial dose, administered once every 4 wk. Max: 180 mcg single inj.
Contraindications
Hypersensitivity to darbepoetin α or other erythropoietin prep.
Special Precautions
Start therapy when Hb conc is <10-11 g/dL. Confirm diagnosis of renal anemia prior to treatment initiation. Assess risk of shock. Monitor Hb conc, hematocrit level, BP at regular intervals. Temporarily discontinue if response of excessive hemopoiesis develops. Closely monitor body fluid & electrolyte balance, renal function, & BP in patient w/ CKD not on dialysis. Administer Fe in patients w/ Fe deficiency. Patients w/ history of hypersensitivity to any drug; allergic predisposition; myocardial/pulmonary/cerebral infarction or those w/ history of these conditions who may experience thromboembolism; HTN. Hypertensive encephalopathy; pure red cell aplasia; hyperkalaemia; shunt occlusion or residual blood in hemodialyzers; blistering & skin exfoliation reactions. Not recommended during pregnancy & lactation. Ped patient. Elderly.
Adverse Reactions
Increased BP, shunt thrombosis/occlusion, headache, malaise. Cerebral infarction &/or hemorrhage; hepatic function disorder &/or jaundice; hypertensive encephalopathy; shock & anaphylactoid reactions; pure red cell aplasia; myocardial &/or pulmonary infarction.
MIMS Class
Haematopoietic Agents
ATC Classification
B03XA02 - darbepoetin alfa ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.
Presentation/Packing
Form
NESP inj 20 mcg/0.5 mL
Packing/Price
1's
Form
NESP inj 40 mcg/0.5 mL
Packing/Price
1's
Form
NESP inj 120 mcg/0.5 mL
Packing/Price
1's
Form
NESP inj 180 mcg/0.5 mL
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in